Annual report [Section 13 and 15(d), not S-K Item 405]

Note 2 - Stock Based Compensation

v3.26.3
Note 2 - Stock Based Compensation
12 Months Ended
Sep. 30, 2026
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

Note 2. Stock Based Compensation

 

Stock-Based Compensation: The Company’s stock-based compensation plans are administered by the Compensation Committee of the board of directors, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the award.

 

On February 23, 2023, the Company’s shareholders approved the Clearfield, Inc. 2022 Stock Compensation Plan (the “2022 Plan”). The 2022 Plan became effective on the date of shareholder approval, and no further awards may be made under the Clearfield, Inc. Amended and Restated 2007 Stock Compensation Plan (the “Prior Plan”) following the effective date of the 2022 Plan. The total number of shares of stock reserved and available for distribution under the 2022 Plan upon approval was 1,461,461 shares, which includes the number of shares remaining for grant and delivery under the Prior Plan, plus any shares subject to outstanding awards under the Prior Plan as of the effective date of the 2022 Plan that were forfeited, cancelled, or settled for cash.

 

The Company recorded related compensation expense for the years ended September 30, 2026, 2025, and 2024 of $4,649,000, $4,597,000, and $4,375,000, respectively. For the year ended September 30, 2026, $4,497,000 of this expense was included in selling, general and administrative expense and $152,000 was included in cost of sales. For the year ended September 30, 2025, $4,434,000 of this expense was included in selling, general and administrative expense and $163,000 was included in cost of sales. For the year ended September 30, 2024, $4,191,000 of this expense was included in selling, general and administrative expense and $184,000 was included in cost of sales. As of September 30, 2026, $5,103,000 of total unrecognized compensation expense related to non-vested awards is expected to be recognized over a period of approximately 2.1 years.

 

Stock Options: The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. During the fiscal year ended September 30, 2026, the Company did not grant any employees non-qualified stock options. During the fiscal year ended September 30, 2025, the Company granted employees non-qualified stock options to purchase an aggregate of 38,198 shares of common stock with a weighted average contractual term of five years, a weighted average three-year vesting term, and a weighted average exercise price of $30.90. During the fiscal year ended September 30, 2024, the Company granted employees non-qualified stock options to purchase an aggregate of 118,706 shares of common stock with a weighted average contractual term of five years, a weighted average three-year vesting term, and a weighted average exercise price of $26.84.

 

The fair value of stock option awards during the years ended September 30, 2026, 2025, and 2024 was estimated as of the respective grant dates using the assumptions listed below:

 

   

Year ended September 30, 2026

   

Year ended September 30, 2025

   

Year ended September 30, 2024

 

Dividend yield

    N/A       0 %     0 %

Weighted average expected volatility

    N/A       58.07 %     61.66 %

Weighted average risk-free interest rate

    N/A       4.20 %     4.55 %

Weighted average expected life (years)

    N/A       5       5  

Vesting period (years)

    N/A       3       3  

 

The expected stock price volatility is based on the historical volatility of the Company’s stock for a period approximating the expected life. The expected life represents the period of time that options are expected to be outstanding after their grant date. The risk-free interest rate reflects the interest rate at grant date on zero-coupon U.S. governmental bonds having a remaining life similar to the expected option term.

 

Options are generally granted at fair market values determined on the date of grant and vesting normally occurs over a three to five-year period. The maximum contractual term is normally five years. Shares issued upon exercise of a stock option are issued from the Company’s authorized but unissued shares. There were 112,489 options vested during the year ended September 30, 2026, 94,426 options vested during the year ended September 30, 2025, and 90,245 options vested during the year ended September 30, 2024. For the year ended September 30, 2026, there were 97,404 stock options that were exercised using a cashless method of exercise. For the year ended September 30, 2025, there were 138,562 stock options that were exercised using a cashless method of exercise. For the year ended September 30, 2024, there were 1,501 stock options that were exercised using a cashless method of exercise. The intrinsic value of options exercised during the years ended September 30, 2026, 2025, and 2024 was $619,000, $2,220,000, and $25,000, respectively.

 

Option transactions under the 2022 Plan during the years ended September 30, 2026, 2025, and 2024 are summarized as follows:

 

   

Number of shares

   

Weighted average exercise price

   

Weighted average fair value

   

Weighted average remaining contractual life (years)

   

Aggregate intrinsic value (in thousands)

 

Outstanding as of September 30, 2023

    254,124     $ 37.04                          

Granted

    118,706       26.84     $ 12.96                  

Exercised

    (1,501 )     12.40                          

Forfeited and expired

    (4,345 )     38.13                          

Outstanding as of September 30, 2024

    366,984     $ 33.83                          

Granted

    38,198       30.90     $ 14.10                  

Exercised

    (138,562 )     18.28                          

Forfeited and expired

    (5,155 )     51.11                          

Outstanding as of September 30, 2025

    261,465     $ 41.30                          

Granted

    -       -       N/A                  

Exercised

    (97,404 )     27.37                          

Forfeited and expired

    (52,304 )     45.33                          

Outstanding as of September 30, 2026

    111,757     $ 51.54               1.23     $ 5,760  

Exercisable as of September 30, 2026

    94,945     $ 56.03               1.07     $ 136  

 

Restricted Stock: The 2022 Plan permits, and the Prior Plan permitted, the Compensation Committee of the board of directors to grant stock-based awards, including stock options and restricted stock, to key employees and non-employee directors. The Company has made restricted stock grants that vest over one to ten years.

 

Restricted stock transactions during the years ended September 30, 2026, 2025, and 2024 are summarized as follows:

 

   

Number of shares

   

Weighted average grant date fair value

 

Unvested shares as of September 30, 2023

    90,575     $ 49.92  

Granted

    137,928       26.65  

Vested

    (58,559 )     39.60  

Forfeited

    (7,737 )     27.84  

Unvested shares as of September 30, 2024

    162,207     $ 34.91  

Granted

    122,577       31.12  

Vested

    (71,691 )     57.35  

Forfeited

    (10,908 )     26.99  

Unvested shares as of September 30, 2025

    202,185     $ 27.64  

Granted

    168,978       29.58  

Vested

    (98,582 )     46.70  

Performance stock units settled into restricted stock

    33,834       30.90  

Forfeited

    (15,129 )     29.49  

Unvested shares as of September 30, 2026

    291,286     $ 22.70  

 

The vesting date fair value of restricted shares vested during the years ended September 30, 2026, 2025, and 2024 was $3,543,000, $2,089,000, and $1,796,000, respectively. The Company repurchased a total of 33,785 shares of our common stock at an average price of $30.18 in connection with payment of taxes upon the vesting of restricted stock previously issued to employees for the year ended September 30, 2026. The Company repurchased a total of 17,497 shares of our common stock at an average price of $28.27 in connection with payment of taxes upon the vesting of restricted stock previously issued to employees for the year ended September 30, 2025. The Company repurchased a total of 15,879 shares of our common stock at an average price of $31.05 in connection with payment of taxes upon the vesting of restricted stock previously issued to employees for the year ended September 30, 2024.

 

Performance Stock Units: During the fiscal year ended September 30, 2026, the Company granted 69,117 performance stock units which entitle the participant to receive one share of the Company’s common stock for each performance stock unit awarded, subject to the achievement of fiscal year 2026 performance goals. Achievement of the goals can result in 50% to 150% of the shares being awarded, with two-thirds of the shares earned being issued as stock subject to restrictions on transfer that will lapse in equal amounts on the first two anniversaries of the settlement date. The Company has determined the fair value per underlying share of the performance stock unit awards to be $29.36 as of the grant date. The fair value of these performance stock unit awards is based on the closing market price of the Company’s common stock on the grant date and is recognized as compensation expense over the vesting period based on the probable number of awards to vest at each reporting date. As of September 30, 2026, the Company determined that the fiscal year 2026 performance goal was not achieved and, accordingly, no compensation expense was recognized for these awards during the year.

 

During the fiscal year ended September 30, 2025, the Company granted 50,747 performance stock units which entitled the participant to receive one share of the Company’s common stock for each performance stock unit awarded, subject to the achievement of fiscal year 2025 performance goals. Achievement of the goals entitled the participant to receive 50%, 100%, or 150% of the shares being awarded, with two-thirds of the shares earned being issued as stock subject to restrictions on transfer that will lapse in equal amounts on the first two anniversaries of the settlement date. The grant date fair value of the performance stock unit awards was $30.90 per share, based on the closing market price of our common stock on the grant date. During the fiscal year ended September 30, 2026, the Company certified the fiscal year 2025 performance goals, which resulted in a payout percentage of 100%. Of the 50,747 performance stock units earned, 16,913 shares of the Company’s common stock vested at settlement and 33,834 performance stock units were settled into restricted stock subject to restrictions on transfer that will lapse in equal amounts on the first two anniversaries of the settlement date.

 

During the fiscal year ended September 30, 2024, the Company granted 47,745 performance stock units which entitled the participant to receive one share of the Company’s common stock for each performance stock unit awarded, subject to achievement of a fiscal year 2024 performance goal. The Company determined the fair value per underlying share of the performance stock unit awards was $26.18 as of the grant date. The fiscal year 2024 performance goal was not achieved, and the performance share units were not earned. Accordingly, no stock-based compensation expense was recognized related to these awards for the year ended September 30, 2024.

 

Performance stock unit transactions during the years ended September 30, 2026, 2025, and 2024 are summarized as follows:

   

Number of shares

   

Weighted average grant date fair value

 

Unvested shares as of September 30, 2023

    -       -  

Granted

    47,745       26.18  

Vested

    -       -  

Forfeited

    -       -  

Unvested shares as of September 30, 2024

    47,745       26.18  

Granted

    50,747       30.90  

Vested

    -       -  

Forfeited

    (47,745 )     26.18  

Unvested shares as of September 30, 2025

    50,747     $ 30.90  

Granted

    69,117       29.36  

Vested

    (16,913 )     30.90  

Performance stock units settled into restricted stock

    (33,834 )     30.90  

Forfeited

    -       -  

Unvested as of September 30, 2026

    69,117     $ 29.36  

 

Employee Stock Purchase Plan: The Clearfield, Inc. 2010 Employee Stock Purchase Plan (“ESPP”) allows participating employees to purchase shares of the Company’s common stock at a discount through payroll deductions. The ESPP is available to all employees subject to certain eligibility requirements. Terms of the ESPP provide that participating employees may purchase the Company’s common stock on a voluntary after-tax basis. Employees may purchase the Company’s common stock at a price that is no less than the lower of 85% of the fair market value of one share of common stock at the beginning or end of each stock purchase period or phase. The ESPP is carried out in six-month phases, with phases beginning on January 1 and July 1 of each calendar year. For the phase that ended on December 31, 2025, employees purchased 9,668 shares at a price of $24.78 per share. For the phase that ended on June 30, 2026, employees purchased 11,032 shares at a price of $24.78 per share. After the employee purchase on June 30, 2026, 101,253 shares of common stock were available for future purchase under the ESPP.